The Program Project for Marrow Transplantation in Leukemia is an integrated multidisciplinary program of basic and clinical research aimed at elucidating the genetic, cellular and environmental factors which includes the development of transplanted hematopoietic and lymphoid progenitor cells with an allogeneic host. This project is principally focused on the distinctive biology of T-cell depleted marrow transplants applied to the treatment of leukemia. The primary emphasis is given to the development of a clearer understanding of the biological forces promoting or limiting engraftment, the development of innovative strategies to prevent graft failure or rejection, and their evaluation in both murine and primate models of transplantation. Research programs are also proposed to investigate cellular systems contributing to resistance to leukemia recurrence and the development of graft/host tolerance. In addition, experimental programs exploring the pathogenesis of CMV infections and new approaches to diagnosis, treatment and prevention of these infections based on recently developed human monoclonal antibodies are proposed. As an extension of this research program, clinical trials are proposed to evaluate both HLA matched and non-identical related as well as matched unrelated T-Cell depleted marrow transplants in the treatment of leukemia and to assess new cytoreductive and immunosuppressive approaches designed to abrogate resistance to engraftment and to further reduce the incidence of leukemia in the post transplant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA023766-15
Application #
3093071
Study Section
Special Emphasis Panel (SRC (B1))
Project Start
1978-08-01
Project End
1993-05-31
Budget Start
1992-09-15
Budget End
1993-05-31
Support Year
15
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824
Kim, Seong Jin; Huang, Yao-Ting; Foldi, Julia et al. (2018) Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12881
Maslak, Peter G; Dao, Tao; Bernal, Yvette et al. (2018) Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv 2:224-234
DeFilipp, Zachariah; Peled, Jonathan U; Li, Shuli et al. (2018) Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2:745-753
Haak, Bastiaan W; Littmann, Eric R; Chaubard, Jean-Luc et al. (2018) Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 131:2978-2986
Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239
Lin, Richard J; Ho, Caleb; Hilden, Patrick D et al. (2018) Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol :
Malard, Florent; Labopin, Myriam; Cho, Christina et al. (2018) Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol 11:127
Luduec, Jean-BenoƮt Le; Kudva, Anupa; Boudreau, Jeanette E et al. (2018) Novel multiplex PCR-SSP method for centromeric KIR allele discrimination. Sci Rep 8:14853
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697

Showing the most recent 10 out of 452 publications